ALKERMES PLC. (ALKS)
Alkermes Announces Positive Topline Results From REVITALYZ℠ Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia
Alkermes Announces Positive Topline Results From REVITALYZ℠ Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia
📈 **POSITIVE** • High confidence analysis (85%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business